Trial: 202101200

Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma

Phase

I (Cancer Control)

Principal Investigator

Van Tine, Brian

Disease Site

Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Non-Hodgkin Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder

Learn more about this study at: clinicaltrials.gov